Ask about this productRelated genes to: MTHFD1 Blocking Peptide
- Gene:
- MTHFD1 NIH gene
- Name:
- methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1
- Previous symbol:
- MTHFC, MTHFD
- Synonyms:
- -
- Chromosome:
- 14q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-23
- Date modifiied:
- 2019-04-23
Related products to: MTHFD1 Blocking Peptide
Related articles to: MTHFD1 Blocking Peptide
- One-carbon metabolism (OCM) is crucial for fetal development, while perfluoroalkyl substances (PFAS) are associated with adverse birth outcomes and lower folate levels. PFAS may compete with folate for receptors, and OCM genes regulate folate metabolism; however, no study examined if OCM variants modified PFAS-birth outcome associations. The study investigated the relationship between OCM variants, prenatal PFAS exposure, and birth outcomes. - Source: PubMed
Publication date: 2026/04/08
Wei Chih-FuChen Mei-HueiLin Ching-ChunLu Tzu-PinChen Chia-YangHsieh Wu-ShiunChen Pau-Chung - One-carbon metabolism is essential for nucleotide biosynthesis and redox homeostasis, and its key enzymes, MTHFD2 and MTHFD1, are aberrantly activated in diverse cancers, particularly acute myeloid leukemia (AML). Herein, we solved the X-ray crystallography of the reported MTHFD inhibitor DS18561882 bound to MTHFD2 and performed systematic structure-activity optimization, leading to the identification of a highly selective MTHFD2 inhibitor (compound ) and a dual MTHFD1/2 inhibitor (compound ). Cocrystal structural analysis revealed that subtle modifications of the aminosulfonamide motif dictate isoform selectivity by reshaping hydrogen bond and hydrophobic networks within the MTHFDs active site. Notably, the dual inhibitor exhibited superior antiproliferative activities across AML cell lines and induced marked tumor regression in MOLM-13 xenograft models with minimal toxicity, outperforming the reference compound DS18561882. Our findings establish rational design principles for isoform-selective and dual MTHFD1/2 inhibitors and highlight a combined MTHFD1/2 blockade as a promising therapeutic strategy for AML. - Source: PubMed
Publication date: 2026/03/20
Lin HaoHe XiangliSun BinLu HaowenLiang JunWang QinghuaLiao JingjingYang XinyuSong ZilanZheng JunkeLu WeiqiangZhang Ao - N6-methyladenosine (m6A) is a prevalent modification of mammalian mRNA. Increasing evidence has documented diverse roles of m6A in normal cell physiology and diseases. However, its functional role in erythropoiesis remains poorly understood. In this study, we found that deletion of Mettl3 using EpoR-Cre mouse led to microcytic/hypochromic anemia due to defective erythropoiesis along with impaired hemoglobin biosynthesis. Mechanically, Mettl3 deficiency disrupted nucleotide biosynthesis which induced DNA damage, leading to apoptosis of CFU-E cells and cell cycle arrest of erythroblasts. Integrated m6A sequencing and RNA-seq analysis along with biochemical studies identified Mthfd1, a key enzyme involved in nucleotide biosynthesis, as a Mettl3 direct target gene. Furthermore, deletion of Mettl3 led to decreased expression of Mthfd1 accompanied by a shortage of nucleotides dTMP and IMP in erythroid cells. Additionally, inhibition of METTL3 in human erythroid cells led to similar phenotypic and molecular changes, indicating conserved role of METTL3 in human and murine erythropoiesis. Our findings have identified a METTL3-m6A-MTHFD1 axis that plays a critical role in erythropoiesis by maintaining genome stability of erythroid cells via regulation of nucleotide biosynthesis. These findings provide important insights into the regulatory mechanisms of erythropoiesis and may have implications for underlying the mechanisms of anemias. - Source: PubMed
Publication date: 2026/03/10
Zhang LinlinZhao HuizhiWang ShihuiWu XuetingLiu DonghaoZhang HengchaoYang QianqianCheng YingWu XiuyunZhao JiangweiZhang ShijieZhang HuanZhang HaojianKang QiaozhenChen LixiangAn XiuliQu Xiaoli - Polycystic ovary syndrome (PCOS) is characterized by reproductive dysfunction and metabolic disturbances, including obesity, insulin resistance, and dyslipidemia. Dietary trans fatty acids, particularly elaidic acid (EA), have been implicated in metabolic disorders, but their role in PCOS pathogenesis remains unclear. - Source: PubMed
Publication date: 2026/02/24
Xu YatingNing LiWang RuyueMa HuaZhao HongtingSi YuLi XiuRen Qingling - Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous malignancy with variable outcomes. Identification of reliable biomarkers is critical for risk assessment and targeted therapy. - Source: PubMed
Publication date: 2026/02/25
Li ChiHan XinliHu XiaoshuangDu ShuruiAn PeihanWang Dao